Email this article The evaluation of Mastodinon efficiency in treatment of hyperprolactinemic syndrome
- Authors: Vishnevsky A.S.1, Safronnikova N.R.1, Melnikova N.U.1, Grigorieva T.A.1
-
Affiliations:
- Center for Preventive Medicine of the Association of Gynecologic Oncologists
- Issue: Vol 49, No 1 (2000)
- Pages: 39-41
- Section: Original Research
- URL: https://journals.rcsi.science/jowd/article/view/88937
- DOI: https://doi.org/10.17816/JOWD88937
- ID: 88937
Cite item
Full Text
Abstract
The clinical efficiency of Mastodinon (“Bionorica”) is studied in management of 33 patients (average age 34,6 years) with different menstrual disfunctions and dysmenorrhea. In 13 patients these disturbances coexisted with hyperprolactinemia.
As a result of 3-month treatment with Mastodinon we noted the normalization of menstrual function in 13 of 17 patients, and the decrease in prolactin serum levels on 10 of 13 women. The prolactin decrease was followed by increase in luteinizing hormone and progesteron, as chosen for ovulatory cycle.
It is found that Mastodinon has the properties of dopaminomimetics and can be concerned as the alternative for synthetic dopaminergic drug therapy (Bromocriptine etc.).
Full Text
##article.viewOnOriginalSite##About the authors
A. S. Vishnevsky
Center for Preventive Medicine of the Association of Gynecologic Oncologists
Author for correspondence.
Email: info@eco-vector.com
Russian Federation, St. Petersburg
N. R. Safronnikova
Center for Preventive Medicine of the Association of Gynecologic Oncologists
Email: info@eco-vector.com
Russian Federation, St. Petersburg
N. U. Melnikova
Center for Preventive Medicine of the Association of Gynecologic Oncologists
Email: info@eco-vector.com
Russian Federation, St. Petersburg
T. A. Grigorieva
Center for Preventive Medicine of the Association of Gynecologic Oncologists
Email: info@eco-vector.com
Russian Federation, St. Petersburg
References
